Is Egrifta (Tesamorelin) Legal in Florida?

What Is Tesamorelin and Why Does Its Legal Status Matter?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth-hormone (GH) secretion. The FDA approved Egrifta in November 2010 specifically to reduce excess abdominal fat (visceral adiposity) in HIV-positive adults with lipodystrophy, making it the only GHRH analogue with full FDA approval for any indication in the United States. [1]

Because tesamorelin sits at the intersection of peptide therapy, hormone regulation, and compounding pharmacy law, patients and clinicians often ask whether it is legal. The short answer: brand-name Egrifta is a lawful Schedule-free prescription drug in every U.S. State, Florida included. Compounded versions require more careful navigation.

The Phase III Data Behind FDA Approval

The approval rested on two randomized, double-blind, placebo-controlled Phase III trials (LIPO-010 and LIPO-011) enrolling 816 HIV-positive adults. At 26 weeks, tesamorelin 2 mg subcutaneous daily reduced visceral adipose tissue (VAT) by a mean of 18% versus a 5% increase in the placebo arm (P<0.001). [2] A subsequent 52-week extension confirmed durability: VAT reduction was maintained at 18.1% from baseline in completers who continued active treatment. [3]

The 2019 reformulation, Egrifta SV (stabilized version), uses a new diluent that eliminates the need for reconstitution with mannitol, improving stability and patient convenience without altering the pharmacokinetic profile. [4]

Why Clinicians Prescribe Tesamorelin Off-Label

Off-label prescribing is legal under federal law and under Florida's medical practice act (Ch. 458 F.S. For MDs, Ch. 459 for DOs). Physicians in Florida routinely prescribe Egrifta outside its labeled HIV-lipodystrophy indication for conditions including non-alcoholic fatty liver disease (NAFLD) related to metabolic dysfunction and age-related visceral adiposity. A 2018 randomized trial published in The Lancet HIV (N=61) found that tesamorelin reduced liver fat fraction by 37% versus 10% with placebo over 12 months (P<0.001) in HIV-positive patients with NAFLD. [5] the drug remains prescription-only regardless of indication.

Federal Legal Framework: FDA Approval and Prescription Status

Egrifta's federal status is unambiguous. The FDA Center for Drug Evaluation and Research (CDER) granted New Drug Application (NDA) 022505 in 2010. [1] The drug is not listed under the Controlled Substances Act and carries no DEA scheduling. Any U.S.-licensed prescriber may write a prescription for it.

The 503A Compounding Pathway

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a customized drug for an individual patient provided: (a) the preparation is based on a valid prescription for an identified patient, (b) the active pharmaceutical ingredient (API) appears on FDA's list of bulk drug substances that may be used in compounding or is a component of an FDA-approved drug, and (c) the compounded preparation is not essentially a copy of an FDA-approved commercial product. [6]

Tesamorelin is the API in an FDA-approved drug (Egrifta). That means a 503A pharmacy using tesamorelin API is compounding an ingredient that is "a component of an FDA-approved drug." Whether the resulting preparation constitutes an "essentially a copy" of Egrifta is the legal question that a prescribing physician and compounding pharmacist must evaluate together. FDA has issued guidance stating that a compounded drug is essentially a copy if it is the same as an FDA-approved product unless there is a "clinical difference" for the specific patient (e.g., a documented allergy to an excipient). [6]

The 503B Outsourcing Facility Pathway

FDA-registered outsourcing facilities (503B) may compound drug products without patient-specific prescriptions and sell to licensed healthcare facilities. For 503B facilities, tesamorelin may be produced only if it appears on FDA's 503B bulk-drug substances list or is demonstrably not a copy of a commercially available product in adequate supply. As of the publication date, tesamorelin has been nominated for the 503B bulk-drug substances list but FDA has not yet finalized its Category 1 (nominated, under review) determination. Prescribers and patients should verify current status directly with the FDA database before sourcing from a 503B facility. [7]

FDA Bulk-Drug Substances List: Current Status

FDA maintains a public list of bulk drug substances nominated for use in compounding. Tesamorelin appears under the nominated-but-under-review category. It is NOT on the final affirmative list that would grant blanket 503B compounding rights. This distinction matters because some online peptide vendors claim legal 503B status without verifiable registration. The FDA's online outsourcing facility registry at accessdata.fda.gov allows anyone to confirm whether a specific facility is legitimately registered. [7]

Florida State Law: What the Florida Board of Pharmacy Requires

Florida does not add a separate peptide-specific statute on top of federal law. Tesamorelin's legality in Florida flows from federal approval and Florida's adoption of federal compounding standards.

Florida Statutes Chapter 465 and the Board of Pharmacy

Chapter 465 of the Florida Statutes governs pharmacy practice. Section 465.0157 specifically addresses compounding and requires that Florida-licensed pharmacies comply with USP standards (USP 795 for non-sterile, USP 797 for sterile preparations) and federal law. [8] Because tesamorelin is administered by subcutaneous injection, any compounded version must meet USP 797 sterile-compounding standards, which require appropriate beyond-use dating, environmental monitoring, and microbial testing.

Florida Prescriber Authority

Any Florida physician (MD or DO), advanced practice registered nurse (APRN) with a prescriptive authority agreement, or physician assistant (PA) with delegated prescriptive authority may write a prescription for Egrifta. Florida does not restrict tesamorelin prescribing to infectious-disease specialists or endocrinologists. A primary care or integrative-medicine clinician may prescribe it provided the prescription reflects sound clinical judgment. [9]

What Florida Does NOT Have

Florida has no state-level ban on tesamorelin. The Florida Board of Medicine has not issued any specific disciplinary guideline singling out tesamorelin as a prohibited substance. This contrasts with anabolic steroids, which carry state-level scheduling (Florida Statute 893.03) on top of federal Schedule III classification. Tesamorelin is not an anabolic steroid.

How to Access Egrifta (Tesamorelin) Legally in Florida

There are three practical routes for a Florida patient.

Route 1: Brand-Name Egrifta Through a Specialty Pharmacy

Theratechnologies (the manufacturer) distributes Egrifta and Egrifta SV through specialty pharmacies. A Florida physician writes a prescription, and the specialty pharmacy handles prior authorization with the patient's insurance. For HIV-positive patients with confirmed lipodystrophy, many insurance plans cover Egrifta under the specialty-drug tier. The FDA label lists the approved dose as 2 mg subcutaneously once daily. [1] Patients self-inject into the abdomen. No refrigeration is required for Egrifta SV after reconstitution for up to 3 hours at room temperature.

Route 2: 503A Compounded Tesamorelin

A Florida-licensed 503A compounding pharmacy may prepare tesamorelin for a specific, identified patient with a valid prescription if the prescriber documents a clinical difference from the commercial product (for example, a reformulation to a different concentration for a patient with needle-site reactions, or an excipient change for a documented allergy). The prescription must be in the prescriber's hands before the pharmacy compounds the preparation. Pharmacies operating without a valid patient-specific prescription are violating federal law, regardless of state location.

Route 3: Telehealth Prescription in Florida

Florida's telehealth statute (Section 456.47 F.S.) permits prescribing for established telehealth relationships. A Florida-licensed telehealth provider may prescribe Egrifta after a virtual clinical encounter that includes a review of relevant labs (IGF-1, fasting glucose, HbA1c), documentation of HIV status and lipodystrophy if targeting the labeled indication, or documented clinical rationale for off-label use. The prescriber must establish a valid patient-prescriber relationship before issuing the prescription. [9]

The HealthRX clinical team uses a three-checkpoint intake framework before prescribing tesamorelin:

1. Indication check. Confirm HIV-associated lipodystrophy for on-label use, or document metabolic/hepatic rationale for off-label use with supporting imaging or labs.
2. Safety screen. Obtain fasting glucose and HbA1c (tesamorelin may impair glucose tolerance), IGF-1, and a history of active malignancy (contraindicated per FDA label).
3. Pharmacy verification. Confirm the dispensing pharmacy is either a licensed Florida specialty pharmacy for brand Egrifta, or a 503A/503B facility with verifiable registration and current USP 797 compliance certification.

Safety Profile and Contraindications Florida Prescribers Must Know

Prescribing tesamorelin, whether brand or compounded, requires attention to its FDA-labeled safety data. The package insert reports the following adverse reactions at incidence >5% in clinical trials: injection site reactions (24.5%), arthralgia (13.3%), pain in extremity (6.6%), peripheral edema (6.6%), and myalgia (5.8%). [1]

Glucose Metabolism Warning

Tesamorelin increases GH secretion, and elevated GH can reduce insulin sensitivity. In the Phase III trials, mean fasting glucose increased by 4.8 mg/dL in the tesamorelin group versus 1.4 mg/dL in the placebo group at 26 weeks. [2] The FDA label carries a warning that tesamorelin may cause glucose intolerance, and the drug is contraindicated in patients with active malignancy given GH's mitogenic properties.

Drug Interactions

Tesamorelin may alter the metabolism of drugs processed by cytochrome P450 enzymes because GH affects CYP3A4 activity. Clinically significant interactions have been reported with corticosteroids, which may reduce tesamorelin's GH-stimulating effect. The FDA label advises monitoring patients on glucocorticoid replacement therapy, as dosage adjustments may be needed. [1]

IGF-1 Monitoring

The Endocrine Society's clinical practice guideline on GH deficiency recommends monitoring IGF-1 levels during any GH-axis treatment to detect supraphysiologic elevations. [10] Though the guideline addresses GH deficiency specifically, the same monitoring principle applies to tesamorelin, which raises IGF-1 by approximately 94 mcg/L (mean change) versus 18 mcg/L with placebo in the Phase III data. [3] A baseline and 3-month IGF-1 measurement is standard practice in Florida telehealth and outpatient endocrinology settings.

Distinguishing Legal Tesamorelin from Unregulated "Research Chemical" Markets

A meaningful volume of tesamorelin is sold online as a "research chemical" in unregulated forms. These products are not pharmaceutical-grade, are not compounded under USP 797, and are not dispensed pursuant to a prescription. Buying or using such products does not fall under any legal compounding exemption.

The FDA has issued multiple warning letters to peptide vendors selling injectable compounds, including GHRH analogues, without a prescription or through unlicensed channels. [11] Florida residents purchasing unregulated tesamorelin from such vendors risk receiving material of unknown purity, potency, and sterility, and the transaction likely violates federal law regardless of the vendor's state of location.

The distinction is straightforward. A legal tesamorelin product in Florida is either (a) brand-name Egrifta dispensed by a licensed pharmacy on a valid prescription, or (b) a compounded preparation from a licensed 503A/503B facility on a valid prescription that meets FDA compounding criteria.

Insurance Coverage and Cost in Florida

Brand-name Egrifta carries a list price above $3,000 per month. Coverage is common for HIV-positive patients with documented lipodystrophy under most Florida Medicaid managed-care plans and many commercial insurers. Prior authorization typically requires documentation of HIV diagnosis, antiretroviral therapy use, and imaging or physical exam findings consistent with visceral fat accumulation.

For patients seeking tesamorelin off-label (e.g., for metabolic NAFLD or age-related VAT increase), insurance coverage is unlikely without an approved indication. Compounded tesamorelin from a 503A pharmacy is generally less expensive than brand Egrifta, but patients must confirm that the compounding pharmacy holds a valid Florida 503A pharmacy license and complies with USP 797 for sterile preparations.

Theratechnologies operates a patient assistance program (PAP) that may reduce or eliminate out-of-pocket costs for eligible uninsured or underinsured HIV-positive patients in Florida. Patients can enroll through the manufacturer's website or by asking their prescriber's office to submit documentation.

Key Takeaways for Florida Patients and Prescribers

Brand-name Egrifta is fully legal in Florida. A valid prescription from any Florida-licensed prescriber with prescriptive authority is sufficient to obtain it from a licensed specialty pharmacy. Compounded tesamorelin is legal under narrow federal conditions: patient-specific 503A compounding with a documented clinical difference from the commercial product, or 503B outsourcing facility production when tesamorelin reaches final affirmative status on the FDA bulk-drug substances list.

No Florida state law adds restrictions beyond federal requirements. The Florida Board of Pharmacy requires USP 797 compliance for all sterile compounded preparations, including tesamorelin.

Before starting therapy, obtain a baseline fasting glucose, HbA1c, and IGF-1. The FDA-approved dose is 2 mg subcutaneously once daily, and the Phase III data show statistically significant VAT reduction by week 26, with a mean 18% decrease from baseline (P<0.001). [2]